Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.
Ticker SymbolAXDX
Company nameAccelerate Diagnostics Inc
IPO dateOct 27, 1993
CEOMr. John (Jack) Phillips
Number of employees107
Security typeOrdinary Share
Fiscal year-endOct 27
Address3950 S Country Club Rd Ste 470 Bldg 3-307
CityDENVER
Stock exchangeBolsa Mexicana de Valores S.A. de C.V.
CountryUnited States of America
Postal code80203
Phone13038638088
Websitehttps://acceleratediagnostics.com/
Ticker SymbolAXDX
IPO dateOct 27, 1993
CEOMr. John (Jack) Phillips
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data